Alternatively Constructed Estrogen Receptor Alpha-Driven Super-Enhancers Result in Similar Gene Expression in Breast and Endometrial Cell Lines.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
27 Feb 2020
Historique:
received: 22 01 2020
revised: 21 02 2020
accepted: 25 02 2020
entrez: 4 3 2020
pubmed: 4 3 2020
medline: 29 12 2020
Statut: epublish

Résumé

Super-enhancers (SEs) are clusters of highly active enhancers, regulating cell type-specific and disease-related genes, including oncogenes. The individual regulatory regions within SEs might be simultaneously bound by different transcription factors (TFs) and co-regulators, which together establish a chromatin environment conducting to effective transcription. While cells with distinct TF profiles can have different functions, how different cells control overlapping genetic programs remains a question. In this paper, we show that the construction of estrogen receptor alpha-driven SEs is tissue-specific, both collaborating TFs and the active SE components greatly differ between human breast cancer-derived MCF-7 and endometrial cancer-derived Ishikawa cells; nonetheless, SEs common to both cell lines have similar transcriptional outputs. These results delineate that despite the existence of a combinatorial code allowing alternative SE construction, a single master regulator might be able to determine the overall activity of SEs.

Identifiants

pubmed: 32120995
pii: ijms21051630
doi: 10.3390/ijms21051630
pmc: PMC7084573
pii:
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
DNA-Binding Proteins 0
ESR1 protein, human 0
Estrogen Receptor alpha 0
FOXM1 protein, human 0
Forkhead Box Protein M1 0
Muscle Proteins 0
TEA Domain Transcription Factors 0
TEAD4 protein, human 0
Transcription Factors 0
TCF12 protein, human 142661-93-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : MOLMEDEX FUN-OMICS
ID : GINOP-2.3.3-15-2016-00007
Organisme : Debrecen Venture Catapult Program
ID : EFOP-3.6.1-16-2016-00022
Organisme : Hungarian Scientific Research Fund
ID : K 129166
Organisme : New National Excellence Program of the Ministry of Human Capacities
ID : ÚNKP-17-3-IV-DE-140
Organisme : New National Excellence Program of the Ministry of Human Capacities
ID : ÚNKP-18-3-III-DE-253
Organisme : Hungarian Scientific Research Fund
ID : PD 124843
Organisme : New National Excellence Program of the Ministry of Human Capacities
ID : ÚNKP-19-4-DE-173

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Cell. 2013 Dec 19;155(7):1521-31
pubmed: 24360275
Cancer Res. 2013 Mar 1;73(5):1570-80
pubmed: 23269278
Nat Commun. 2018 Mar 5;9(1):943
pubmed: 29507293
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Pharmacol Rev. 2006 Dec;58(4):685-704
pubmed: 17132848
Cell. 1988 Oct 7;55(1):145-56
pubmed: 3167974
Cell. 2014 Oct 9;159(2):358-73
pubmed: 25303530
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
World J Surg Oncol. 2015 Jun 25;13:208
pubmed: 26108802
Genome Biol. 2006;7(9):R82
pubmed: 16961928
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Genome Res. 2013 Jan;23(1):12-22
pubmed: 23172872
Mol Cancer Res. 2016 Sep;14(9):849-58
pubmed: 27259717
BMC Genomics. 2008 Oct 16;9:488
pubmed: 18925949
Biochem J. 2011 Oct 1;439(1):15-25
pubmed: 21916844
Genome Biol. 2012 Oct 03;13(10):R88
pubmed: 23034120
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Nature. 2012 Jan 04;481(7381):389-93
pubmed: 22217937
Science. 2018 Jul 27;361(6400):
pubmed: 29930091
Cell. 2008 Mar 21;132(6):958-70
pubmed: 18358809
Nature. 2010 Sep 23;467(7314):430-5
pubmed: 20720539
Mol Syst Biol. 2010 Dec 21;6:456
pubmed: 21179027
Cell Rep. 2016 Feb 9;14(5):1169-1180
pubmed: 26832411
Gynecol Oncol. 2012 Oct;127(1):241-8
pubmed: 22710073
Genes Chromosomes Cancer. 2002 Dec;35(4):311-7
pubmed: 12378525
Nat Commun. 2017 Jul 17;8:16069
pubmed: 28714474
Nat Genet. 2015 Jan;47(1):8-12
pubmed: 25547603
Nucleic Acids Res. 2017 Apr 20;45(7):3693-3706
pubmed: 27994038
Tumour Biol. 2017 Jun;39(6):1010428317703924
pubmed: 28651494
Amino Acids. 2015 Jul;47(7):1341-52
pubmed: 25813938
Cell. 1986 Sep 26;46(7):1053-61
pubmed: 3463433
Bioinformatics. 2004 Nov 22;20(17):3246-8
pubmed: 15180930
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Nat Genet. 2011 Jan;43(1):27-33
pubmed: 21151129
Mol Endocrinol. 2004 Jun;18(6):1411-27
pubmed: 15001666
Nucleic Acids Res. 2001 Jul 15;29(14):2905-19
pubmed: 11452016
Mol Cell Biol. 2010 Aug;30(16):3943-55
pubmed: 20547749
Cell. 2014 Oct 9;159(2):374-387
pubmed: 25303531
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
PeerJ. 2014 Nov 18;2:e654
pubmed: 25426335
Cell Rep. 2014 Oct 9;9(1):234-247
pubmed: 25263550
Cell. 1990 Dec 21;63(6):1267-76
pubmed: 2124518
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Exp Cell Res. 2017 Nov 15;360(2):105-112
pubmed: 28843961
Hum Reprod Update. 2007 Jul-Aug;13(4):405-17
pubmed: 17584823
Cell. 2005 Jul 15;122(1):33-43
pubmed: 16009131
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
J Biotechnol. 2019 Jun 20;299:13-20
pubmed: 31039369
Cell Rep. 2014 Jun 12;7(5):1434-1442
pubmed: 24857666
BMC Bioinformatics. 2010 Aug 06;11:415
pubmed: 20691053
Int J Cancer. 2015 Apr 15;136(8):1863-73
pubmed: 25219463
EMBO J. 2011 May 13;30(13):2569-81
pubmed: 21572391
Oncol Lett. 2018 Jul;16(1):395-401
pubmed: 29928427
BMC Med Genomics. 2011 Jan 12;4:6
pubmed: 21226949
Cancer Res. 2012 Jul 15;72(14):3593-606
pubmed: 22593193
Trends Cancer. 2017 Apr;3(4):269-281
pubmed: 28718439
Steroids. 2000 May;65(5):227-51
pubmed: 10751636
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Maturitas. 1996 May;23 Suppl:S65-9
pubmed: 8865143
Genes Dev. 2010 Jan 15;24(2):171-82
pubmed: 20080953
Breast Cancer Res. 2009;11(6):213
pubmed: 19909494
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Mol Cells. 2018 Jun;41(6):506-514
pubmed: 29754476
Cancer Res. 2016 Jul 1;76(13):3773-84
pubmed: 27197147
Cell. 2017 Mar 23;169(1):13-23
pubmed: 28340338

Auteurs

Dóra Bojcsuk (D)

Genomic Medicine and Bioinformatic Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, 4032 Debrecen, Hungary.

Gergely Nagy (G)

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Bálint László Bálint (BL)

Genomic Medicine and Bioinformatic Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, 4032 Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH